EVFM
Evofem Biosciences, Inc.
-0.00 (-7.50%)0.01USD26.0K成交股數981K市值–本益比(近四季)0.1股價營收比-45.4%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 2.6M+212% | 899K-87% | 5.0M+10% | 4.8M+16% | 845K-77% | 7.1M-93% | 4.5M-12% | 4.2M+69% | 3.6M | 100M | 5.1M | 2.5M |
| 營業成本 | 511K | 410K | 905K | 755K | 365K | 1.5M | 869K | 769K | 684K | – | 1.9M | 2.3M |
| 毛利 | 2.1M+342% | 489K-91% | 4.0M+12% | 4.1M+20% | 480K-84% | 5.6M | 3.6M+13% | 3.4M+1955% | 2.9M | – | 3.2M | 165K |
| 毛利率 | 80.6% | 54.4% | 81.7% | 84.4% | 56.8% | 78.7% | 80.7% | 81.5% | 81.0% | – | 63.0% | 6.7% |
| 研發費用 | – | – | – | – | – | 649K | 332K | 270K | 594K | – | 614K | 402K |
| 銷售管理費用 | 1.8M | 2.4M | 2.1M | 1.8M | 2.4M | 3.4M | 3.1M | 2.3M | 2.8M | – | 3.2M | 4.9M |
| 營業利益 | −2.5M-861% | −4.6M+356% | 951K-139% | −1.3M-10% | 327K-111% | −1.0M | −2.4M-31% | −1.4M-81% | −2.8M | – | −3.6M | −7.3M |
| 營業利益率 | -94.5% | -508.2% | 19.2% | -25.9% | 38.7% | -14.1% | -54.3% | -33.4% | -78.9% | – | -69.5% | -298.5% |
| 稅後淨利 | −11.0M-1254% | −5.5M+80% | −1.6M-34% | −1.8M-232% | 956K-120% | −3.0M | −2.4M-104% | 1.4M-116% | −4.8M | – | 66.0M | −8.6M |
| 淨利率 | -419.1% | -607.9% | -31.7% | -37.0% | 113.1% | -42.8% | -52.6% | 32.5% | -133.5% | – | 1,291.2% | -348.2% |
| 稀釋 EPS | -0.08 | -0.04-157% | -0.01-50% | -0.01 | 0.00-100% | 0.07 | -0.02-120% | 0.00-100% | -0.16 | – | 0.10 | -5.43 |
| 稀釋股數 | 137M | 133M | 120M | 120M | 6.16B | 80.0M | 96.5M | 1.61B | 31.2M | – | 730M | 1.6M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 285K | 1.5M | 840K | 748K | 221K | 741K | 722K | 692K | 689K | – | 410K | 636K |
| 應收帳款 | 2.5M | 560K | 4.4M | 4.9M | 1.1M | 9.8M | 5.4M | 4.6M | 4.3M | – | 6.3M | 5.2M |
| 存貨 | 2.2M | 1.9M | 1.7M | 1.9M | 2.3M | 1.6M | 1.5M | 1.1M | 1.3M | – | 2.5M | 3.7M |
| 總資產 | 7.5M | 7.4M | 13.8M | 14.4M | 12.9M | 23.8M | 23.9M | 8.6M | 8.2M | – | 13.3M | 14.1M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 90.0M | 80.2M | 84.0M | 79.2M | 77.7M | 90.3M | 90.1M | 73.2M | 74.2M | – | 67.9M | 69.7M |
| 股東權益 | −87.5M | −77.6M | −75.1M | −69.6M | −69.6M | −71.3M | −70.9M | −69.3M | −70.7M | – | −56.4M | −55.7M |
| 負債比 | 1,196.6% | 1,077.0% | 608.2% | 550.8% | 603.2% | 379.4% | 376.2% | 855.8% | 903.5% | – | 509.5% | 495.5% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 2.3M | – | – | 560K+355% | – | – | – | 123K | – | – | – |
| 資本支出 | – | 2K | – | – | – | – | – | – | 14K | – | – | – |
| 自由現金流 | – | 2.3M | – | – | – | – | – | – | 109K | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 255.7% | – | – | – | – | – | – | 3.0% | – | – | – |
營收拆解 2023 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2023 年度 · 18.2M
| Phexxi | 18.2M | 100.0% | +8.3% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 20.2M | +4.2% | 391K | 1.9% | 0.00 | −2.0M |
| FY2024 | 19.4M | +6.3% | −8.9M | -45.8% | -0.11 | −3.9M |
| FY2023 | 18.2M | +8.2% | 53.0M | 290.8% | 0.05 | −9.0M |
| FY2022 | 16.8M | +104.2% | −76.7M | -455.5% | -167.42 | −70.8M |
| FY2021 | 8.2M | +1748.4% | −205M | -2,489.0% | -23.63 | −150M |
| FY2020 | 446K | – | −142M | -31,907.8% | -2.12 | −107M |
| FY2019 | 0 | – | −80.0M | –% | -1.99 | −55.3M |
| FY2018 | – | – | −126M | –% | -5.74 | −56.5M |